Mitchell C. Posner to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Mitchell C. Posner has written about Tumor Necrosis Factor-alpha.
Connection Strength
0.769
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.164
-
Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
Score: 0.104
-
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb; 75(2):332-8.
Score: 0.080
-
Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
Score: 0.064
-
Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 2008 Mar; 15(3):133-9.
Score: 0.060
-
Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB. Int J Oncol. 2007 Dec; 31(6):1519-28.
Score: 0.060
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.048
-
Control of gene therapy by MDR1 and EGR1 promoter sequences in transcriptional targeting by chemotherapy (Review). Int J Oncol. 2004 Mar; 24(3):731-6.
Score: 0.046
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.043
-
Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. Am Surg. 2003 Jan; 69(1):24-7.
Score: 0.043
-
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
Score: 0.042
-
Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 2006 Jan 01; 13(1):1-6.
Score: 0.013